The Kentucky Medicaid program relies on published AWPs to calculate Medicaid drug reimbursement rates. Dey published significantly inflated AWPs for its drugs albuterol, cromolyn sodium, ipratropium bromide and other inhalation drugs used to treat asthma and chronic obstructive pulmonary disease. At times the AWPs were inflated by 1,200 percent.
Dey then created a “Reimbursement Cost Comparison Worksheet” that permitted the Dey sales force to graphically demonstrate the increased profits that Medicaid pharmacy providers would realize if they switched to Dey drugs. The combination of both practices caused the Kentucky Medicaid program to pay substantially more for Dey’s drugs than the actual cost of the drugs paid by Kentucky pharmacists.
Read the Kentucky AG’s news release about Kentucky’s settlement with Dey.
Read other coverage about pharmaceutical fraud:
– Department of Justice Recovers $3B in False Claims Act Lawsuits in FY 2010
– Former Chairman of KV Pharmaceutical First Exec to be Banned From Healthcare Programs
– Pharmaceutical Company Mylan Settles False Claims Lawsuit With Massachusetts AG for $2.6M
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.